Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)
10 févr. 2020 08h00 HE
|
Oculis SA
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone that has the potential to treat retinal diseases The Phase 2 (DX-211) study provides a clinical proof-of-concept of OCS-01...
Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in Patients with Diabetic Macular Edema (DME) at Angiogenesis, Exudation, and Degeneration 2020
22 janv. 2020 08h00 HE
|
Oculis SA
LAUSANNE, Switzerland, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
07 oct. 2019 08h00 HE
|
Oculis SA
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME) LAUSANNE, Switzerland, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Oculis...
Oculis Announces Appointment of Leading Ophthalmology Specialists to Scientific Advisory Board
17 sept. 2019 08h00 HE
|
Oculis SA
-- Eric D. Donnenfeld, M.D., internationally recognized expert and pioneer in refractive, cornea and cataract surgery -- Ramin Tadayoni, M.D., Ph.D., renowned professor and ophthalmologist in the...